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PENILAIAN KEBERKESANAN RAWATAN  KLINIKAL DAN KOS 
PERBUATAN LANGSUNG DIKALANGAN PESAKIT-PESAKIT LUAR 
YANG MENGHIDAP PENYAKIT DIABETES MELLITUS JENIS 2 DI 
HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRAK 
 
Diabetes mellitus kian menjadi masalah yang besar dalam kesihatan awam, 
terutamanya pada masa ini apabila sebahagian besar daripada perbelanjaan penjagaan 
kesihatan dilbelanjakan ka atas rawatan penyakit ini dan komplikasinya. kajian ini 
merupakan satu kajian cerapan  bersifat prospektif terhadap pesakit diabetes jenis 2 
yang betujuan untuk menilai modaliti rawatan ,kawalan glisemik, dan faktor-faktor  
yang berkaitan dengan perkembangan komplikasi makrovaskcular dan mikrovaskular 
penyakit tersbut, dan menilai kos perubatan langsung bagi merawat pesakit diabetes 
jenis 2 di Hospital Universiti Sains Malaysia (HUSM). Semua pesakit diabetes jenis 
2 yang dating ke  klinik diabetes HUSM dan mereka yang seterusnya diberi rawatan 
susulan di klinik  tersebut dimasukkan dalam kajian ini. 
 
 Sejumalah 1077 orang pesakit yang menghidap diabete jenis 2 telah 
dimasukkan  ke dalam kajian ini, dengan julat umur mereka antara 18 hingga 88 
tahun, dan umur median 58 tahun. Majoriti pesakit terdiri daripada wanita, dan 
kurang daripada separuh pesakit-pesakit itu mempunyai sijil tinggi persekolahan. 
Tempoh min diabetes ialah 11.2 tahun, min HbA1c ialah 8.7%, manakala min tahap 
glukosa darah berpuasa ialah 7.8 mmol/L, dan glukosa plasma pascaprandial 
ialah10.0 mmol/L. 
 
Kajian in telah mendapati bahawa 26.3% daripada pesakit – pesakit 
mempunyai kawalan optimum (HbA1c≤ 7.0%) dan 73.7% mempunyai kawalan yang 
tidak mencukupi (HbA1c > 7%). Pada keseluruhannya, 747 pesakit (69.4%) 
diberikan rawatan ubat antidiabetik bersama makanan, manakala 30.6% diberikan 
suntikan insulin semata-mata, atau suntikan bersama agen hipoglisemia. Kajian juga 
mendapati faktor-faktor  yang mempengaruhi tahap HbA1c terdiri daripada umur, 
bangsa dan rawatan antidiabetes. Bagaimanapun, faktor-faktor yang mempengaruhi 
glukosa plasma berpuasa adalah umur dan merokok, manakala faktor-faktor yang 
mempengaruhi glukosa plasma pascaprandial adalah gender dan tempoh menghidap 
 xxix 
diabetes. Tambahan lagi, kajian ini telah mendapati bahawa faktor-faktor berubah 
yang mempengaruhi perkembangan komplikasi makrovaskular terdiri daripada umur, 
tahap pendidikan, indeks jisim badan (BMI), lilitan pinggang, rawatan antidiabetes, 
tekanan darah diastolik, dan kolesterol. Bagaimanapun, komplikasi mikrovaskular 
dipengaruhi oleh umur, trigliserid dan klearans kreatinin.  
 
Retinopati berlaku pada kadar 39% dalam kalangan pesakit-pesakit yang 
dikaji, dan mereka yang dipengaruhi oleh tempoh penyakit tersebut, neutropati, 
trigliserid, dan klearans kreatinin. Kejadian neuropati adalah 54.7%, dan faktor risiko 
utama mereka ialah tempoh menghidap diabetes, dan wujudnya retinopati, 
bertambahnya HbA1c dan klearans kreatinin. Nefropati telah dikesan delam 90.7% 
daripada pesakit- pesakit, dipengaruhi terutamanya oleh gender, trigliserid dan 
klearans kreatinin. 
 
Hasil kajian ini juga menunjukkan bahawa hipertensi berlaku dalam 92.7% 
daripada pesakit yang dikaji, dan hanya 47.2 % daripada mereka mencapai sasaran 
tekanan darah yang optimum. Daripada sejumlah itu, 104 ( 22.1 %) mendapat 
rawatan ACEI, 76 (16.1 %) mendapat rawatan ARB dan CCB, 72 (15.3 %) mendapat 
rawatan gabungan ACEI dan CCB. 
 
Daripada keputusan awal, dapatlah disimpulkan bahawa banyak protokol 
pengurusan telah gagal untuk mencapai dan mengekalkan tahap glisemik yang 
optimum. Terapi antidiabetis boleh memperbaiki glisemia, tetapi perbezaan dalam 
kalangan rawatan antidiabetes yang berlainan didapati tidak signifikan. Intervensi 
secara betul diperlukan untuk mengubah rawatan dan mencapai kawalan glisemik 
yang lebih baik. Untuk mengurangkan atau  menangguhkan perkembangan 
komplikasi vaskular, strategi yang betul diperlukan bagi pengesanan awal, dan 
rawatan yang agresif terhadap faktor-faktor risiko boleh diubah suai termasuk 
menggunakan rawatan-rawatan antidiabetes, antihipertensi, antidislipedemia, dan 
antiplatelet. Bagi retinopati,neuropati, dan nefropati strategi kesihatan awam 
diperlukan untuk mengurangkan kesan faktor risiko, dan mengurangkan komplikasi- 
komplikasi tersebut. Kadar prevalens hipertensi adalah sangat tinggi, dan tekanan 
darah lebih daripada separuh pesakit-pesakit itu adalah di luar kawalan.  
 xxx 
Hasil kajian ini menunjukkan bahawa kos tahunan purata rawatan pesakit luar 
adalah RM 1730.7 bagi seorang pesakit, dengan kos minimum sebanyak RM 546 
bagi seorang pesakit, dan maksimumnya RM 5432.8. Daripada jumlah keseluruhan 
kos rawatan, 59.2 % (RM 1023.9) meliputi kos ubat-ubatan, 31.1% (RM 537.41)  
dibelanjakan ke atas kos penyelidikan makmal, 7.1 % (RM 124.28) meliputi kos 
tahunan lawatan ke klinik, dan 2.6% (RM 45.15) meliputi kos personel perubatan. 
Tahap glukosa darah yang terkawal baik akan dapat mengurangkan kos rawatan 
jagaan diabetes, justeru, dapat mengurangkan kos rawatan pesakit luar. Banyak 
perhatian dan usaha seharusnya ditujukan kepada mendapatkan pengetahuan tentang 
beban ekonomi diabetes di HUSM dan di hospital-hospital lain. 
 
Kata kunci: Diabetes mellitus jenis2, Kos perubatan langsung, Hipertensi, 
Retinopati,  Nefropati, komplikasi makrovaskular. 
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ASSESSMENT OF THE CLINICAL TREATMENT OUTCOMES AND 
DIRECT MEDICAL COSTS AMONG TYPE 2 DIABETES MELLITUS 
OUTPATIENTS AT THE HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
 
 
Diabetes mellitus (DM) is becoming a major public health problem, 
especially now that a large proportion of health care expenditure is being spent on 
the treatment of this disease and its complications. This was a prospective 
observational study of diabetes type 2 patients with the objectives of assessing the 
treatment modalities, glycaemic control and the factors associated with the 
development of macro and microvascular complications, and evaluating the direct 
medical costs of treating diabetic type 2 patients at the Hospital Universiti Sains 
Malaysia (HUSM). All of the type 2 diabetes patients who attended and were 
followed-up at the HUSM diabetes clinic were included in this study. 
 
A total of 1077 patients with type 2 diabetes were recruited for this study, with ages 
ranging from 18 to 88, and a median age of 58 years. The majority of the patients 
were female, and less than half of the patients had more than high school certificates. 
The mean duration of diabetes was 11.2 (+6.81) years, the mean glycosylated 
haemoglobin (HbA1c) was 8.7% (+2.34), the mean fasting blood glucose level was 
7.8 mmol/l (+3.72), and the mean postprandial plasma glucose level was 10.0 mmol/l 
(+4.38). 
 
It was found that 26.3% of the patients had optimal control (HbA1c <7%) and 
that 73.7% had inadequate control (HbA1c >7%). Overall, 747 patients (69.4%) were 
on oral antidiabetes medications, whereas 30.6% were on insulin injections, alone or 
with oral hypoglycaemic agents. The factors that influenced HbA1c levels were 
found to be age, race and antidiabetic medication. However, the factors that 
influenced fasting plasma glucose were age and smoking while the factors that 
influence postprandial plasma glucose were gender and duration of diabetes. 
Furthermore, it was found that the variable factors influencing the development of 
macrovascular complications were age, education level, body mass index (BMI), 
waist circumference, antidiabetic medication, diastolic blood pressure (BP), and 
 xxxii 
cholesterol level. However, microvascular complications were influenced by age, 
triglycerides, and creatinine clearance rate.  
 
Retinopathies appeared at the rate of 39% among the study patients, and these 
were influenced by duration of the disease, neuropathies, triglycerides and creatinine 
clearance rate. The prevalence of neuropathies was 54.7%, and their main risk factors 
were duration of diabetes, the presence of retinopathies, and increased levels of 
HbA1c and creatinine clearance rate. Nephropathies were detected in 90.7% of the 
patients and were mainly affected by gender and creatinine clearance rate.  
 
The present findings also show that hypertension was prevalent in 92.7% of 
the study patients, and only 471 (47.2%) of them achieved the optimal blood pressure 
targets.  Of those, 104 (22.1%) were on angiotensin converting enzyme inhibitors 
(ACEI), 76 (16.1%) were on angiotensin receptor blockers (ARB) and calcium channel 
blockers CCB, and 72 (15.3%) were on combinations of ACEI and CCB.  
 
From the initial results it was concluded that numerous management 
protocols have failed to achieve and maintain proper glycaemic levels. Antidiabetic 
therapy can improve glycaemia, but the differences between the different antidiabetic 
medications were not significant. Intended medication interventions are required to 
alter treatments and achieve better glycaemic control. In order to reduce or delay the 
development of vascular complications, proper strategies are required for early 
detection and aggressive treatment of the modifiable risk factors, including the 
appropriate use of antidiabetes, antihypertension, antidyslipidaemia, and antiplatelet 
treatments. For retinopathies, neuropathies, and nephropathies, public health 
strategies are required in order to reduce the risk factor effects, and reduce their 
prevalence. Early detection and appropriate management can reduce the burden of 
these complications. The prevalence rate of hypertension was very high, and the BP 
of more than half (527) of the patients was out of control.  
The current findings revealed that the average annual direct medical cost of 
outpatient treatment was RM 1730.7 per patient, with a minimum cost of RM 546 
per patient, and a maximum of RM 5432.8. Of the total treatment cost, 59.2% (RM 
1023.9) covered the cost of the medications, 31.1% (RM 537.41) the cost of 
laboratory investigations, 7.1% (RM 124.28) covered the cost of annual visits to the 
 xxxiii 
clinic, and 2.6% (RM 45.15) covered the cost of medical personnel. Good control of 
blood glucose levels leads to decreased treatment costs in diabetes care, and hence a 
decrease in outpatient treatment costs. More attention and efforts should be directed 
towards gaining knowledge of the economic burden of diabetes in HUSM and 
elsewhere. 
 
Key words: Type 2 Diabetes mellitus, Direct Medical Cost, Hypertension, 
Retinopathy, Nephropathy, Macrovascular Complications.  
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1.0 Introduction 
1.1 Background 
Diabetes mellitus is a disease affecting nearly 10% of the global population 
above 20 years of age. Type 2 diabetes mellitus (type 2 DM) is the most prevalent 
form of diabetes. It accounts for about 90% to 95% of all Diabetes Mellitus (DM) 
cases and particularly affects overweight individuals usually over 40 years of age 
(Canadian Diabetic Association, 2005). Although a disease of adults, type 2 DM is 
now being diagnosed more frequently in children and adolescents (Canadian 
Diabetic Association, 2005). Type 2 DM is often part of a metabolic syndrome that 
includes obesity, elevated blood pressure and high levels of blood lipids. 
Type 2 DM is a chronic, progressive disease characterized by insulin 
resistance and pancreatic β-islet cell failure. Three specific abnormalities contribute 
to hyperglycemia in type 2 DM: impaired insulin secretion, increased hepatic glucose 
production, and decreased insulin-stimulated uptake of glucose in peripheral tissues. 
In type 2 DM, the early phase of insulin secretion is lost, mainly resulting in the 
characteristically increased postprandial glucose. Increased insulin resistance also 
frequently occurs in people who are obese, and is associated with the metabolic 
syndrome (Evans and krenz, 2001). 
The progressive aging of the world‟s population, resulting from better control 
of communicable diseases and improved nutrition and hygiene, has also played an 
important role in the marked increase in non-communicable diseases such as type 2 
DM. The increase of prevalence and incidence of diabetes are attributable to several 
factors including the aging population, urbanization, sedentary lifestyles increased 
survival rates, and continued and increasing rates of obesity (Motala et al., 2003). 
 3 
 
Type 2 DM is a major and growing health problem in most countries (Harris 
et al., 1998) that causes considerable loss due to disability, premature mortality and 
loss of productivities. Diabetes is in fact a serious vascular disease with poor 
prognosis, and that it is not only a disease characterized by elevated blood glucose 
(Marja-Ritta et al., 2002). Type 2 DM is already the leading cause of blindness 
among working-age adults, of end-stage renal disease and of non-traumatic loss of 
limb (Ulbrecht et al., 2004; Williamson et al., 2004). The American Diabetes 
Association (2008) reports that this disease is the fifth
 
leading cause of death by 
disease in the United States. The consequences of persistant hyperglycemia can 
cause serious damage in nerves and blood vessels, the latter leading to macro- and 
microcomplications. Ragucci et al. (2003) reported that patients with diabetes 
mellitus carry an increased risk of two to four times greater for heart attack, stroke 
and other complications related to poor circulation. These complications can be 
reduced by normalisation of glucose levels (The diabetes control & complication trial 
research group, 1993; United Kingdom Prospective Study Group, 1998) this 
normalisation being the ultimate focus of all diabetes treatments. The overall 
treatment of type 2 DM is to prevent acute and chronic complications while 
maintaining a high quality of life.  
As the disease progresses, many patients with type 2 DM will eventually be 
unable to adequately achieve or maintain glycaemic control, even through 
monotherapy or combination of oral therapies are employed. The reason for 
diminishing antihyperglycaemic effects with oral agents over time is multifactorial 
and includes progressive loss of β-cell function (Turner et al., 1999; Wright et al., 
2002), comorbidities, lifestyle factors, and possibly glucotoxicity (Kuritzky, 2006). 
In most cases, patients on oral antidiabetic therapy will require not only an increase 
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in dosage but also the addition of a second or third oral agent (Banerjee and Singh, 
2002).
 
As the number and dosage of oral antidiabetic medications increases, the side 
effect profile, regimen complexity, and expenses rise commensurately. 
 
1.2 Prevalence of diabetes in the world 
Type 2 DM is rapidly rising as a global health
 
care problem that threatens to 
reach pandemic levels by 2030. In 2003, an estimated 194 million (5.1%) adults had 
diabetes worldwide and 314 million (8.2%) people had impaired glucose tolerance 
(Sicree et al., 2003). This prevalence increased to 6.0 % and 7.5 % in 2007 and is 
predicted to increase to 7.3 % and 8.0 % by 2025 (Sicree et al., 2006). 380 million 
people are expected to have diabetes in 2025 (Sicree et al., 2006). 
The prevalence of diabetes is higher in developed countries than in 
developing countries, but the developing world may be hit hard by the escalating 
diabetes epidemic in the future. Increased urbanisation and economic development in 
developing countries have already contributed to a substantial rise in diabetes (WHO, 
2003). This is likely to continue and will be a significant factor in the forthcoming 
global epidemic of diabetes. While diabetes is most common among the elderly in 
many populations, prevalence rates are rising at an alarming rate among 
comparatively young and productive populations in the developing world 
(International Diabetes Federation, 2005). 
 
1.3 Prevalence of diabetes in Asia 
Asia is the major site of a rapidly emerging diabetes epidemic (Wild et al., 
2004; Sicree et al., 2006). Roughly 80% of people with diabetes are in developing 
countries, of which India and China share the largest contribution (Ramachandran et 
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al., 2009). Traditional estimates based on population growth and ageing and rate of 
urbanisation in Asia show that India and China will remain the two countries with 
the highest numbers of people with diabetes 79.4 million and 42.3 million, 
respectively by 2030 (Wild et al., 2004). The further rapidly developing Asian 
nations like Singapore, Malaysia, Thailand and those making up Indochina will 
experience the surge (Zaini, 2000). 
 
1.4 Diabetes in Malaysia 
 
In Malaysia, the Third National Health and Morbidity Survey (NHMS III, 
2006) showed that prevalence of type 2 DM for adults aged 30 years old and above 
was found to be 14.9 % in 2006, upped by almost 79.5% in the space of 10 years 
from 1996 to 2006. 
In Malaysia, there is a growing public concern due to the escalation with 
number of people with diabetes while complication rates and associated diseases 
amongst diabetics are high. In addition, high prevalence of complications such as 
blindness, end stage renal disease, lower extremity amputations as well as premature 
cardiovascular disease, stroke and premature mortality related to poor control of 
blood glucose (Mafauzy, 2005). 
Malaysia has a multiethnic population is expected to reach around 33.7 
million by the 2020. The three main racial components of this region are Malays, 
Chinese and Indians are well represented in this country. If China and India are 
balanced to exceed the world's prevalence rate of type 2 DM, their respective 
counterparts in Malaysia may be much worse. The evidences so far indicate that the 
migrant status as well as socioeconomic and lifestyle changes are strong indicators to 
diabetes (National Health and Morbidity Survey, 1996). 
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1.5 Effectiveness of treatment in diabetes 
          Improved glucose control can improve long-term outcomes. Within the last 
decade, new treatments and glycaemic goals have created an opportunity to better 
manage this prevalent chronic disease.  
For the purpose of evaluating the treatment outcomes and complications, 
several studies have evaluated percentage of diabetic control with each regimen 
drugs. The United Kingdom prospective diabetes study 33 (1998) demonstrated that 
each percentage point reduction in HbA1c was associated with a 35% reduction in 
microvascular complications, a 25% reduction in diabetes-related deaths and a 7% 
reduction in all cause mortality. The evaluation should review the previous 
treatments, and the past and present degrees of glycaemic control. Laboratory
 
tests 
suitable to the evaluation of each patient‟s medical condition should be performed 
(American Diabetes Association, 2006 and 2007). Vivian and Ali (2000) suggested 
that combination treatment with once daily metformin, rosiglitazone improves 
glycaemic control, insulin sensitivity, and β-cell function more effectively than 
treatment with metformin alone. Acarbose was shown to be an effective addition 
therapy in combination with insulin. After 24 weeks of treatment, HbA1c was 
reduced by 0.40%, and insulin requirements were considerably lowered in patients in 
whom acarbose was added to their insulin regimen versus those remaining on insulin 
monotherapy (Coniff et al., 1995). 
 
1.6 Economic burden of type 2 diabetes mellitus  
1.6.1Economic cost of type 2 diabetic mellitus   
         The exact costs of diabetes are not easy to pin down but estimations can be 
obtained according to 3 levels which include: 
 7 
 
1. Cost directly linked to the diagnosis and management of diabetes without 
complications. 
2. Costs generated by complications of diabetes. These are difficult to quantify 
because diabetes is linked to micro and macro vascular diseases such as heart 
disease, kidney failure, eye disease and amputation. Moreover, diabetes may 
add a cost of care by complicating other unrelated medical situations like 
infections, accidents and surgery. 
3. Indirect costs correlated with the quality of life and the economic productivity 
which can be somehow estimated by the degree of disability. 
The direct healthcare costs of diabetes are high
 
and are continuing to rise. 
They are rising because the
 
prevalence of diabetes is increasing, and treatment is
 
becoming more sophisticated and polypharmacy is becoming more
 
common. It is 
suspected that direct healthcare costs for the
 
diabetic disease already dominate 
healthcare budgets, particularly
 
in developed countries and increasingly in 
developing countries (Williams, 2005). 
 
It is now well recognized that preventing or 
delaying the onset
 
of type 2 DM results in considerable cost reduction.  
           There are many reasons for studying the economic burden of diabetes. Firstly, 
diabetes is costly especially in direct medical costs. Secondly, resources that
 
can be 
devoted to prevention and control of diabetes are limited
 
because of the "opportunity 
cost" of doing so. Thirdly, the need for resources will continue
 
to increase because of 
the increasing prevalence of diabetes
 
and thus, demand for comprehensive care and 
new treatments. These
 
estimates do not include the cost of undiagnosed diabetes. 
Neither
 
do they include the size of immeasurable costs, such as
 
human pain and 
suffering (American Diabetes Association, 2003). 
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Research from Costa Rica by Morice et al. (1999) showed that people with 
diabetes made 1.55 times more medical visits than people without diabetes. Wong et 
al. (2002) showed that the treatment costs can be brought to a minimum without 
affecting effective diabetes care with good control of blood glucose level which leads 
to a sharp decrease in consultation and treatment procedures, hence, reducing the 
outpatient treatment.  
Type 2 DM is a serious and expensive disease and one key issue in reducing 
costs is most certainly to address the associated late complications at an early stage. 
Comprehensive diabetes disease management program should
 
improve patient 
outcomes, decrease costs,
 
and ensure member and provider satisfactions. Although 
medication treatment costs are increased by combination therapy, this cost is 
expected to be partially balanced by a reduction in the costs of treating long-term 
diabetes complications (Ward et al., 2004). 
 
1.6.2 Cost management of type 2 diabetes mellitus 
           Diabetes mellitus is a chronic disease that has been recognized by the 
Malaysian government as a major public health problem with far reaching 
consequences not just for its adverse impact on the health of Malaysians, but also for 
the economic burden it places on the health care system. Diabetes mellitus presents a 
high burden for individuals and society. This burden is not only related to health care 
costs, but also to indirect costs caused by loss of productivity from disability and 
premature mortality. Medical expenditures for people with diabetes are 2–3 times 
higher than that for those not affected by diabetes (Rubin et al., 1994). 
Effective disease management programmes that aim to prevent complications 
could potentially lead to cost savings in managed care settings (Selby et al., 1997). 
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Hayward et al. (1997) found that patients taking insulin had 2.4 more diabetic 
outpatient visits, used 300 more glucose test strips, and had slightly higher laboratory 
costs per year than patients receiving sulphonylureas.  
Johnson et al. (2006) found that metformin, alone or in combination, was the 
most frequently dispensed oral antidiabetic medication. A longer duration of diabetes 
was associated with increased use of oral medications and insulin therapy. Insulin 
was used in approximately 12% of patients with type 2 DM and was associated with 
approximately three times higher expenditure on diabetes testing supplies compared 
with patients on oral antidiabetic medications (Johnson et al., 2006). 
 
1.7 Research questions: 
The questions to be examined in this study are as follows: 
 What is the most regimen of antidiabetic medication that achieved target 
glycaemic control? 
 What are the factors affecting the glycaemic control? 
 What are the factors that play a role in macrovascular complications 
development?   
 What are the factors that enhance the microvascular complications? 
 What are the factors that enhance the retinopathy, neuropathy and 
nephropathy complications? 
 What are the prevalence and control levels of hypertension in diabetic 
patients? 
 What are the antihypertensive drug regimens which lead to achievement of 
the targets of treatment among diabetic patients? 
 What are the annual direct medical costs of type 2 diabetic treatment? 
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1.8 Rationale of the study 
As highlighted earlier, the management of type 2 DM is always challenging 
for both patients and clinicians. Therefore, it is imperative to document the 
effectiveness of the treatment modalities available for controlling diabetes mellitus in 
Malaysia. This study was rationalized by some emerging facts about type 2 DM in 
Malaysia. The high prevalence of diabetes is associated with poor glycaemic control 
and a high rate of complications. This study will provide good baseline data about 
the current status of diabetic patients at the Hospital Universiti Sains Malaysia 
(HUSM) concerning the degree to which they control their glucose level. Knowledge 
of patients glucose status included {glycated hemoglobin (HbA1c), fasting plasma 
glucose (FPG) & postprandial plasma glucose (PPG)}, body mass index (BMI), lipid 
profile [triglycerides (TG), low density lipoproteins (LDL), total cholesterol, high 
density lipoproteins (HDL)}, and blood pressure will help decision makers in 
evaluating the current epidemic level of diabetes at the HUSM.  
Understanding the effectiveness of antidiabetes medications along with the 
factors of glycaemic control on the development of complications may allow 
planners to draw up proper plans for the overall improvement of this disease.  
 
1.9 Significance of the study  
This study followed and evaluated the outcomes of diabetic patients on 
antidiabetic medications over a period of one year. The effectiveness of antidiabetic 
medications and the annual direct medical costs in one year were also evaluated. 
Therefore, this study may also help in the assessment of the economic burden of type 
2 DM in the HUSM in general. Previous studies have reported on the factors 
influencing glycaemic control and microvascular and macrovascular complications, 
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but these studies were limited, only mentioned a few factors, and did not follow-up 
the patients. Hence, a large scale multifactorial study was needed. To the best of our 
knowledge, there are no reports on the Asian population which extensively studied 
the factors influencing glycaemic control and micro and macrovascular 
complications. Furthermore, the current study also took into account clinical 
outcomes from an economic perspective, which gives this study an important edge as 
it could be used to draw a road map for the clinical treatment and costs of treatment 
for type 2 DM. It estimated the annual budgetary impact on treating type 2 DM. The 
main aims of this study were to obtain a profile of type 2 DM patients in the HUSM 
in order to assist in type 2 DM management programmes and to provide data for an 
economic evaluation. Accordingly, this study will provide a rough estimate of the 
direct medical costs incurred in the treatment of type 2 DM from the perspective of 
the HUSM management. This study also provides data about the prevalence and 
prescribing patterns of drugs used in treating this disease and it was also designed to 
help predict future consumption patterns.  
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1.10 Study objectives  
1.10.1 General Objectives 
         To evaluate clinical treatment outcomes of type 2 diabetic patients and 
estimate the annual direct medical costs of type 2 diabetic outpatients at Hospital 
Universiti Sains Malaysia (HUSM) in year 2008. 
 
1.10.2 Specific objectives 
1. To evaluate the following parameters: glycaemic control (HbA1c), fasting 
plasma glucose (FPG), postprandial plasma glucose (PPG), body mass index 
(BMI), waist circumference (WC), low density lipoprotein (LDL-C), high- 
density lipoprotein, (HDL-C), total cholesterol, triglyceride and blood pressure in 
diabetic patients attending outpatient clinics in  HUSM. 
 
2. To compare the effectiveness of various antidiabetic regimens with regards to 
achievement of treatment targets (through glycaemic control). 
 
3. To evaluate the factors influencing glycaemic control which include personal    
characteristics and health characteristics. Personal characteristics include age,     
gender, race, smoking history, alcohol consumption history, physical activity,    
education level and family history and health characteristics include BMI, WC, 
duration of diabetes, patterns of diabetic medications which affect glycaemic 
control (HbA1c, FPG & PPG). 
 
4. To evaluate the factors that lead to the enhanced development of macrovascular 
complications, such as personal characteristics, health characteristics and clinical 
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variables (HbA1c, FPG, PPG, BMI, WC, LDL-C, HDL-C, total cholesterol, 
triglycerides, blood pressure, and creatinine clearance rate.   
 
5. To evaluate the factors that lead to the development of microvascular 
complications, such as personal characteristics, health characteristics and clinical 
variables (HbA1c, FPG, PPG, BMI, WC, LDL-C, HDL-C, total cholesterol, 
triglycerides, blood pressure, and creatinine clearance rate.  
 
6.  To evaluate the factors that lead to the enhanced development of retinopathy, 
neuropathy and nephropathy complications, such as personal characteristics, 
health characteristics and clinical variables (HbA1c, FPG, PPG, BMI, WC, LDL-
C, HDL-C, total cholesterol, triglycerides, blood pressure, and creatinine 
clearance rate.   
 
7. To determine prevalence and control of hypertension among diabetic patients 
attending the outpatients clinics at HUSM. 
 
8.  To calculate the annual direct medical costs among type 2 diabetes mellitus 
patients at Hospital Universiti Sains Malaysia.  
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PART ONE: ASSESSMENT OF THE CLINICAL TREATMENT 
OUTCOMES OF TYPE 2 DIABETES MELLITUS 
OUTPATIENTS AT THE UNIVERSITI SAINS MALAYSIA 
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2.1 Background  
The main focus of this literature review is on type 2 DM outpatients. The 
purpose of the review will be to focus on research been done in the following areas: 
1)  The background about type 2 diabetes disease.  
2)  Clinical variable characteristics of type 2 diabetes patients.  
3) The factors that exert effects on glycaemic control. 
4)  Effectiveness of antidiabetic medications. 
      5)  The factors related to macrovascular complications. 
6)  The factors related to microvascular complications.  
7)  The factors related to retinopathy, neuropathy& nephropathy. 
8) Hypertension in patients with type 2 DM. 
Diabetes is one of the most growing public health problems which cause 
major morbidity and mortility cases all over the world. Centre for Disease Control 
and Prevention (2006) described diabetes as an „epidemic of our time that threatens 
to spiral out of control unless early, focused preventative actions are taken‟. The 
challenge for health professionals and governments encompasses economic, social, 
and health planning in developed nations as well as in newly developed or 
developing countries, irrespective of culture or location.  
 
2.2 Definition of type 2 diabetes mellitus 
 Type 2 diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycaemia caused by defects in insulin production, action or both (National 
Diabetes Information Clearinghouse, 2008). Symptoms of diabetes mellitus include 
frequent urination (polyuria), excessive thirst (polydipsia), extreme hunger 
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(polyphagia), unusual weight loss, increased fatigue, irritability and/or blurry vision 
(American Diabetic Association, 2003).  
 
2.3 Diagnosis and classification of diabetes mellitus 
Diagnoses of diabetes according to the American Diabetic Association (2007) 
criteria for the diagnosis of diabetes mellitus are as follows; 
1. FPG ≥126 mg/dl (7.0 mmol/l).  
2. Symptoms of hyperglycemia and casual plasma glucose ≥ 200 mg/dl (11.1mmol/l).   
Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of hyperglycemia include polyuria, polydipsia, and unexplained 
weight loss. 
3. Two hours plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test 
should be performed as described by the World Health Organization, using a glucose 
load containing the equivalent of 75 g anhydrous glucose dissolved in water. 
 
2.4 Epidemiology of type 2 diabetes mellitus 
Type 2 DM is usually preceded by a long period of asymptomatic 
hyperglycemia that may last for years. In this prediabetic state, postprandial levels 
are mildly elevated whereas fasting blood glucose can usually be maintained within 
the near-normal range. The elevation of postprandial levels is used for the definition 
of impaired glucose tolerance (IGT), a nonspecific reversible stage. About 30% of 
these subjects progress to overt diabetes within 10 years (Unwin et al., 2002). 
Elevation of fasting glucose is used for the definition of impaired fasting glucose 
(IFG). In some individuals β-cells compensate for insulin resistance by increased 
insulin secretion, and type 2 DM does not develop. However, in a large number of 
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prediabetic individuals, multiple defects in insulin action and /or insulin secretion 
gradually lead to sustained hyperglycemia. As a consequence of insulin resistance, 
the β-cell produce increased amounts of insulin, and compensatory hyperinsulinemia 
maintains normoglycemia. When β-cell compensation to insulin resistance fails, 
decompensated hyperglycaemic state develops. Thus, type 2 diabetic subjects have 
relative insulin deficiency. Usually such individuals do not need insulin treatment to 
survive. 
Epidemiological studies had already identified “diabetes epidemic” in 1970s. 
Bennett et al. (1971) was reported that the extremely high prevalence of type 2 DM 
in Pima Indians and also in the Micronesian Nauruans in the Pacific (Zimmet et al., 
1977), and subsequently in other Pacific and Asian island populations (Zimmet, 
1992). These studies showed that transition from traditional lifestyle to western way 
of life resulted in obesity, lack of exercise, changes in the diet, and finally to type 2 
DM. Several studies have shown that type 2 DM has reached epidemic proportions in 
several developing countries as well as in Australian Aboriginals (O‟Dea et al., 
1991), African Americans, and Mexican Americans (Burke et al., 2001). Large 
variations in the prevalence of type 2 DM in different populations can be attributed 
to environmental as well as genetic determinants. 
Lately, type 2 DM was regarded as a disease of the middle-aged and the 
elderly. However, evidence is accumulating that onset in subjects aged under 30 
years is increasing. Even children and adolescents are diagnosed to have type 2 DM 
(Alberti et al., 2004) for example, among the children in Japan type 2 DM is already 
more common than type 1 and accounts for 80% of childhood diabetes (Kitagawa et 
al., 1998). In the United States between 8% and 45% of newly presenting children 
and adolescents have type 2 DM (Laakso, 2008). 
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An epidemic of type 2 DM is determined not only by an increase in the 
incidence but also by mortality rates. Although cardiovascular complications in 
nondiabetic subjects have significantly reduced in the United States during the last 
decades this is not the case in diabetic patients, particularly among women, (Gu et 
al., 1999). 
 
 
2.5 Risk factors for type 2 diabetes mellitus 
The identification of risk factors is essential for the successful 
implementation of primary prevention programs. Risk factors for type 2 DM can be 
classified as modifiable and nonmodifiable (Table 2.1). Subjects who subsequently 
develop diabetes have multiple adverse changes in risk factor levels. 
Table 2.1.Risk factors for type 2 DM 
Modifiable    Non modifiable 
Obesity    Ethnicity 
Central obesity Age 
Lack of physical activity Sex 
Smoking Genetic factors 
Alcohol abstinence Family history of type 2 DM 
Low fiber in the diet Prior gestational diabetes 
High saturated fat in the diet Prior glucose intolerance 
 History of cardiovascular disease 
 History of hypertension 
 History of dyslipidaemia 
 Low birth weight 
Source: Laakso (2008) page 7. 
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  2.5.1 Modifiable risk factors 
Visceral adiposity leads to the development of type 2 DM. The obesity is risk 
factor for developing type 2 DM. Boyko et al. (2000) in their study of Japanese 
Americans patients showed that intra-abdominal fat area remained a significant 
predictor of diabetes incidence even after adjustment for body mass index, total body 
fat area, and subcutaneous fat area and other risk factors for diabetes. Interestingly, 
high insulin resistance and low insulin secretion predicted diabetes independently of 
directly measured visceral adiposity suggesting that visceral adiposity could 
contribute to the development of diabetes through actions independent of its effect on 
insulin sensitivity. Van Dam et al. (2001) reported that in Dutch patients the 
association between abdominal obesity and hyperglycemia was stronger in the 
presence of a parental history of diabetes.  
In study by Knowler et al. ( 2002) mentioned that a minimum of 7% weight 
loss or weight maintenance in combination with a minimum of 150 minutes weekly 
physical activity resulted in 58% reduction in the incidence of diabetes. Physical 
inactivity is considered the most important risk factor for the development of type 2 
DM. Physical activity reduces insulin resistance and total and visceral fat mass (Kay 
and fiatarone, 2006).  
A combination of several lifestyle factors, including low body mass index (< 
25 kg/m
2
), a diet high in cereal fiber, polysaturated fat and low in saturated fat and 
trans fats and glycaemic load,  regular exercise, abstinence from smoking and 
moderate alcohol intake, were associated with a reduction of type 2 DM incidence. 
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2.5.2 Non modifiable risk factors 
The prevalence and incidence of type 2 DM are strongly related to age. The 
age is a risk factor for developing type 2 DM. In fact, about 50% of type 2 diabetic 
patients are over 60 years old (Laakso, 2008). Ethnicity is a strong determinant of 
diabetes occurrence. In Chinese, the prevalence of type 2 DM is 1% whereas in Pima 
Indians it is > 50% in the adult population, possibly due to genetic influences or due 
to interaction between genes and environment. No systematic effects of gender on 
the prevalence and incidence of type 2 DM observed. Previous abnormality of 
glucose tolerance, a history of gestational diabetes and a family history are all strong 
predictors of type 2 DM. Interestingly, the presence of other disease states or 
conditions, for example, hypertension and dyslipidemia increase the risk of type 2 
DM (Laakso, 2008). Associations between low birth weight and increased risk of 
type 2 diabetes in adult life have been reported in various populations (Barker, 2004). 
 
2.6 Pathogenesis of type 2 diabetes mellitus 
2.6.1 Pathophysiology of hyperglycemia 
Insulin is the hormone for regulating blood glucose. In general, 
normoglycaemia is sustained by the balanced interplay between insulin secretion and 
the efficacy of insulin actions. In the fasting state, the major part of glucose is created 
by the liver, and roughly half of it is used for brain glucose metabolism. The residue 
is taken up by various tissues, mainly muscle and for a minor part adipose tissue. In 
this situation insulin levels are low and have no substantial effect on muscle glucose 
uptake. The normal liver is capable of rising glucose production four fold or more, 
and the main effect of the relatively low insulin levels is to control liver glucose 
production (Stumvoll et al., 2008). After a meal, insulin is secreted in bigger 
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amounts, which reducing liver glucose production level further, and will lead to an 
enhancement of muscle glucose uptake (Stumvoll et al., 2008). The normal 
pancreatic cell is capable of adjusting to changes in insulin action, that is, a decrease 
in insulin action is accompanied by upregulation of insulin secretion. When the 
adaptation of the β-cell is not enough, the subjects will develop impaired glucose 
tolerance (IGT) or type 2 DM. Weyer et al. (1999) have shown that β-cell 
dysfunction is critical in the pathogenesis of type 2 DM. It is of note that even small 
increases in fasting and postprandial glucose occur in people with insulin resistance, 
which should stimulate insulin release. Thus, when insulin action decreases the 
system normally compensates by increasing β-cell function, in the face of higher 
glucose (Stumvoll et al., 2003).  
 
2.6.2 Insulin resistance 
Insulin resistance is present when the natural effects of insulin are subnormal 
for both glucose disposals in skeletal muscle and suppression of endogenous glucose 
production primarily in the liver (Dinneen et al., 1992). In the fasting state, however, 
muscle accounts for only a small amount of glucose disposal while endogenous 
glucose production is responsible for all of the glucose appearing in plasma. In type 2 
diabetic patients and in patients with impaired fasting glucose (IFG) endogenous 
glucose production is accelerated (Weyer et al., 1999).  
Insulin resistance is strongly associated with obesity. A number of hormones, 
cytokines and metabolic fuels, such as nonesterified free fatty acids (NEFA) 
originate in the adipocyte and reduce insulin action. In obese subjects, adipocytes are 
large, which provide them resistance to the ability of insulin to suppress lipolysis, 
especially in deep subcutaneous fat. In addition, elevated release and circulating 
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levels of NEFA and glycerol, both of which aggravate insulin resistance in skeletal 
muscle and liver (Boden, 1997). 
 
2.6.3 Insulin secretion in type 2 diabetes mellitus 
 
In type 2 diabetic patients, plasma glucose levels are raised; and accordingly, 
fasting plasma insulin was elevated. While the insulin levels sometimes increase 
slightly after a meal in type 2 diabetic patients this is considerably less than normal. 
In a study by Gerich (1998) reported that in which glucose levels have been raised by 
glucose infusions (hyperglycaemic clamps) to comparable levels in diabetic subjects 
and controls, it has become clear that second-phase insulin secretion is roughly 25% 
(IGT) to 50% decreased in type 2 DM. First-phase secretion is generally completely 
lost. In normoglycaemic first-degree relatives insulin secretion is also diminished but 
to a lower extent, presumably on a genetic basis (Pimenta et al., 1995). It is suspected 
that upon acquisition of insulin resistance (obesity, physical inactivity) the pancreas 
that has already lower secretory capabilities can adapt less than normal, which might 
lead to decreased glucose tolerance or diabetes. It has been commonly suggested that 
various mechanisms might further aggravate β-cell insulin secretory dysfunction, 
among which glucose toxicity and lipotoxicity (Stumvoll et al., 2008) 
 
2.6.4 Glucose toxicity 
Over time, insulin secretion appears to decrease in most diabetic patients, it 
has been proposed that glucose itself is toxic to β-cells. In pancreas β-cells oxidative 
glucose metabolism will also lead to the formation of reactive oxygen species (ROS), 
which would damage β-cells. Indeed, β-cells have low amounts of catalase and 
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superoxide dismutase, enzymes which normally metabolise the ROS (Robertson et 
al., 2003).  
 
2.6.5 Lipotoxicity 
Free fatty acids (FFA) extremely increase insulin secretion and chronic FFA 
overload reduces β-cell function. Type 2 DM subjects have frequently increased FFA 
due to insulin resistance to lipolysis. It is currently obvious that high glucose inhibits 
β-cell fatty acid oxidation, which may lead to accumulation of long-chain coenzyme 
A (LC-CoA) (Robertson et al., 2004).  
 
2.7   Heredity in type 2 diabetes mellitus 
A positive family history confers a two to three fold increased risk for the 
disease with a 15% to 30% risk to develop type 2 DM or IGT in first degree relatives 
of type 2 DM subjects (Pierce et al., 1995). The risk is even higher (around 60% by 
the age of 60 years) if both parents have diabetes (Tattersal and Fajans, 1975).  
 
2.8 Genetic factors in type 2 diabetes mellitus 
The polygenic nature of diabetic disease has it difficult to dissect individual 
genes conferring increased risk for diabetes. Type 2 DM has a strong genetic 
component and most Asian diabetic patients have a first-degree relative with diabetes 
(Ng et al., 2001). 
Ramachandran et al. (2009) noted that most of the loci originally associated 
with diabetes in European populations have been replicated in Asian populations. 
Most genetic variants related with type 2 DM seem to be related to insulin secretion 
rather than insulin resistance, and several of the risks are associated with reduced 
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islet-cell function (Frayling, 2007; Florez, 2008; Yasuda et al., 2008; Ramachandran 
et al., 2009). 
 
2.9 Diabetic outpatients 
Diabetic outpatient is defined as the patient who receives services in the 
hospital for less than 24 hours, who is registered on the hospital records as an 
outpatient, and who receives outpatient hospital services, other than supplies or 
prescription drugs alone, from the hospital. Outpatient clinics are an important part 
of every hospital because of following check-up. Outpatient clinics are where the 
decision to admit a patient is taken. Reduction of inpatient length of stay creates 
more work for outpatient clinics. Through frequent visits, the work in these units 
becomes well-organised and coordinated with the work of doctors in the hospital. 
Diabetes services are largely outpatient based. A complex local network of 
services is required to encompass the needs of all people with diabetes throughout 
their lifelong pathway of care. A center requirement for all patients is support for 
self-efficacy, which necessitates effective, continuing patient education programmes 
and compliance influences glycaemic control (Chen et al., 2004).  
 
2.9.1 Compliance of type 2 diabetes mellitus 
Therapeutic compliance is adherence of the patient to treatment indications 
prescribed by the physician. It is necessary to evaluate not only therapy compliance 
but also the non-medical indications. Kravitz et al. (1993) studied that the level of 
adherence to exercise, diet, and the administration of medication in patients with 
chronic diseases such as diabetes mellitus. They found frequencies of noncompliance 
of 19%, 69%, and 91%, respectively. In diabetic outpatients the compliance is very 
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difficult to define. People with diabetes are poorly compliant with dietary and 
exercise recommendations and that primary non-compliance with medication is 
common (Cradock, 2004). 
The diabetic outpatients services are different from diabetic inpatients in: 
 
2.9.1 (a) Diet 
Diet plays an essential role in the therapeutic strategy to keep patients with 
diabetes in good glycaemic control and prevent microvascular and macrovascular 
complications. The management of diabetes has been prescribing dietary 
recommendations for the treatment of diabetes since many years. Although the 
importance and the scientific basis of these recommendations are very well 
recognized, their conversion into daily routine is very difficult. 
 In diabetic inpatients dietitians used more information from medical records to 
make clinical judgment than diabetic outpatients dietitians. 
 In diabetic inpatients dietitians are more likely to identify nutrients related 
problems via information from medical records while outpatients dietitians more 
frequently identify specific behaviorals goals whearesa inpatients dietitians 
recommend general goals.  
 
2.9.1(b) Exercise  
The compliance of exercise is very important in diabetic patients because 
exercise is beneficial in diabetic patients for the following reasons: 
1. Regular aerobic exercise decreases the dosage or need for insulin or oral       
    antihyperglycaemic agents. 
2.  It reduces cardiovascular risk factors. 
